Group 1 - The board of directors of Yantai Zhenghai Biological Technology Co., Ltd. held its eighth meeting of the fourth session on August 4, 2025, via telecommunication, with all 8 directors present [1] - The meeting approved the company's 2025 semi-annual report and its summary, confirming that the preparation process complies with relevant laws and regulations, and accurately reflects the company's actual situation [2][3] Group 2 - The board unanimously agreed to amend the company's articles of association and related rules, and to change the business scope, with details to be disclosed on the designated information disclosure website [3][5] - The board accepted the resignation of non-independent director Ni Ting and nominated Xu Yueli as a candidate for the non-independent director position [3][4] Group 3 - The board decided to dissolve the Strategic and Investment Committee, transferring its responsibilities to the board itself to enhance decision-making efficiency for major investments and financing [4] - The board approved several governance documents, including the establishment of a "Management System for Departing Directors and Senior Management" and modifications to various existing governance rules, all receiving unanimous support [5][6][7][8][9] Group 4 - The company plans to hold its first extraordinary shareholders' meeting of 2025 on August 27, 2025, to review the proposals discussed in the board meeting [9]

Group 1 - The fourth meeting of the supervisory board of Yantai Zhenghai Biological Technology Co., Ltd. was held on August 4, 2025, via communication, with all three supervisors present [1][2] - The supervisory board approved the procedures for the preparation and review of the company's 2025 semi-annual report, confirming that the report accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The voting results showed unanimous support, with 100% of the attending supervisors voting in favor of the resolutions [2][3] Group 2 - The company plans to amend relevant provisions of its articles of association and change its business scope, which will be submitted for review at the first extraordinary shareholders' meeting of 2025 [2][3] - The company also intends to abolish the "Rules for Supervisory Board Meetings," with the details to be disclosed on the designated information disclosure website [2][3]

烟台正海生物科技股份有限公司 第一章 总则 第一条 为进一步加强烟台正海生物科技股份有限公司（以下简称"公司"）与投资者 和潜在投资者（以下统称"投资者"）之间的信息沟通，促进投资者对公司的了解和认同， 完善公司治理结构，规范公司投资者关系管理工作，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）等法律、行 政法规、规范性文件的有关规定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流和诉求 处理等工作，加强与投资者和潜在投资者之间的沟通，增进投资者对公司的了解和认同，以 提升公司治理水平和企业整体价值，实现尊重投资者、回报投资者、保护投资者的相关活动。 第三条 公司投资者关系管理工作应严格遵守《公司法》、《证券法》等有关法律、法 规、规章及深圳证券交易所有关业务规则的规定。 第四条 公司进行投资者关系活动应当建立完备的投资者关系管理档案制度，投资者关 系管理档案至少应当包括下列内容： （一）投资者关系活动参与人员、时间、地点； 烟台正海生物科技股份有限公司 投资者关系管理制度 （二）投资者关系活 ...

Core Points - The document outlines the major transaction decision-making system of Yantai Zhenghai Biological Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1] - The system aims to clarify the responsibilities and powers of the shareholders' meeting, board of directors, and general manager to enhance operational efficiency [1] Chapter 1: General Principles - The company must adhere to the Company Law and the Shenzhen Stock Exchange's rules while making transaction decisions [1] - Transactions include asset purchases or sales, external investments, financial assistance, guarantees, leasing, management contracts, donations, debt restructuring, licensing agreements, R&D project transfers, and rights waivers [1] Chapter 2: Transaction Approval Authority - Transactions exceeding certain thresholds must be submitted to the board of directors for review, including those where the total asset amount exceeds 10% of the latest audited total assets or where the transaction amount exceeds 50 million yuan [2][3] - Transactions that meet specific criteria, such as involving assets over 50% of total audited assets or generating profits over 50% of the latest audited net profit, must be submitted to the shareholders' meeting for approval [4] - For equity transactions that change the scope of consolidated financial statements, the entire asset and revenue of the corresponding company must be considered [4] - The company must hire qualified accounting firms to audit financial reports for equity transactions and qualified asset appraisal firms for non-cash asset transactions [5] - If the total asset amount or transaction amount reaches 30% of the latest audited total assets within 12 months, it must be disclosed and submitted for shareholder approval [6] - Financial assistance transactions require approval from two-thirds of the board and may need to be submitted to the shareholders' meeting under certain conditions [6] Chapter 3: Miscellaneous - The decision-making standards outlined in the document must be followed unless conflicting with national laws and regulations [7] - The company’s shareholders, directors, and independent directors have the right to supervise and question the general manager's actions [8] - The document will be implemented upon approval by the shareholders' meeting and is subject to interpretation by the board of directors [8]

Core Viewpoint - The financing and external guarantee management system of Yantai Zhenghai Biological Technology Co., Ltd. aims to protect investors' rights, regulate financing and guarantee behaviors, control asset operation risks, and ensure financial safety and stable development of the company [2][3]. Group 1: General Provisions - The system applies to the company and its wholly-owned and controlling subsidiaries [2]. - Financing refers to indirect financing from financial institutions, including various forms such as comprehensive credit, working capital loans, and bank guarantees [3]. - External guarantees involve providing guarantees, asset pledges, and other forms of security for other entities or individuals [3]. Group 2: Basic Regulations for External Guarantees - External guarantees must comply with relevant laws and the company's articles of association, following principles of equality, voluntariness, fairness, integrity, and mutual benefit [3]. - External guarantees are subject to unified management, and branches cannot provide guarantees without approval [3]. - Any external guarantee requires approval from the shareholders' meeting or the board of directors [3]. Group 3: Financing Approval Process - The finance management department is responsible for managing financing applications and conducting preliminary reviews [4]. - Financing amounts are limited to 10% of the latest audited net asset value for certain approvals and 20% for others, with higher amounts requiring board and shareholder approval [4][5]. - If the asset-liability ratio exceeds 70%, financing must be approved by the shareholders' meeting [5]. Group 4: External Guarantee Application and Investigation - Before deciding on an external guarantee, the company must assess the credit status of the guaranteed party and analyze the associated risks [6]. - The applicant must submit a guarantee application detailing the debt situation, business or project, risk assessment, and necessary documentation [6][7]. - The finance management department conducts a thorough investigation of the applicant's financial status and creditworthiness [7]. Group 5: Review of External Guarantees - External guarantees undergo a review process involving the finance management department and the board of directors, which assesses the financial status and risks associated with the guaranteed party [9][10]. - Guarantees exceeding certain thresholds require shareholder approval, particularly if they exceed 10% of the latest audited net assets or involve high-risk entities [10][11]. Group 6: Guarantee Contracts - Written guarantee contracts must be established after board or shareholder approval, detailing the nature of the debt, obligations, and liabilities [13][14]. - The finance management department must review the legality and completeness of guarantee contracts, ensuring compliance with laws and regulations [14][15]. Group 7: Execution and Risk Management - The finance management department is responsible for monitoring the execution of financing and guarantee contracts, ensuring compliance with the stipulated purposes [16][17]. - Continuous assessment of the financial status and operational changes of the guaranteed party is required to manage risks effectively [17][18].

Core Points - The document outlines the regulations governing the trading of shares by controlling shareholders, actual controllers, directors, and senior management of Yantai Zhenghai Biological Technology Co., Ltd. [1] - The regulations are based on various laws and guidelines, including the Company Law, Securities Law, and specific rules from the Shenzhen Stock Exchange [1][2]. Group 1: Definitions and Scope - The controlling shareholder is defined as a shareholder holding more than 50% of the company's total capital or having significant influence over shareholder meetings [2]. - The actual controller is defined as a natural person or legal entity that can control the company's actions through investment relationships or agreements, even if they do not hold a majority of shares [2]. - The regulations apply to the trading behavior and information disclosure of controlling shareholders, actual controllers, directors, and senior management [1][3]. Group 2: Trading Behavior Management - Controlling shareholders, actual controllers, directors, and senior management must notify the board secretary in writing before trading shares, and the board secretary must verify the company's disclosure and significant matters [3]. - They are prohibited from using others' accounts or providing funds to trade the company's shares [4]. - There are specific periods during which directors and senior management cannot trade shares, such as 15 days before the annual or semi-annual report announcements [4]. Group 3: Shareholding Restrictions - Directors and senior management cannot transfer shares within one year of the company's stock listing or within six months after leaving their positions [4]. - Controlling shareholders and actual controllers are restricted from reducing their holdings if the company is under investigation for securities violations or facing potential delisting [5]. - The total number of shares that controlling shareholders and actual controllers can reduce through centralized bidding within any 90-day period is limited to 1% of the company's total shares [5]. Group 4: Information Disclosure - Controlling shareholders and actual controllers must report their share reduction plans to the stock exchange 15 trading days before the first sale [8]. - They must disclose the number of shares to be reduced, the time frame, price range, and reasons for the reduction [9]. - Any significant changes in shareholding must be reported within two trading days after the transaction [10]. Group 5: Miscellaneous Provisions - The regulations will be executed in accordance with national laws and the company's articles of association [11]. - The board of directors is responsible for interpreting these regulations and they will take effect upon approval by the board [11].

General Principles - The purpose of the independent director system is to standardize the behavior of independent directors and clarify the rights and responsibilities between the company and independent directors, based on relevant laws and regulations [1] - Independent directors are defined as those who do not hold any other positions in the company and have no direct or indirect interests that could affect their independent judgment [1][2] Independence and Qualifications - The board of directors must include three independent directors, with at least one being a professional accountant [2] - Individuals who have direct or indirect interests in the company, such as major shareholders or their relatives, are prohibited from serving as independent directors [2][3] Nomination and Election - Independent director candidates can be proposed by the board of directors or shareholders holding at least 1% of the company's shares, and must be elected by the shareholders' meeting [4][5] - The nomination process requires the consent of the nominee and a thorough understanding of their qualifications and background [5][6] Responsibilities of Independent Directors - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice to enhance decision-making [18][19] - They have special rights, including the ability to hire external consultants and propose meetings [19][20] Rights and Obligations - The company must provide necessary working conditions and support for independent directors to fulfill their duties [16][17] - Independent directors are entitled to the same rights as other directors, including access to information and resources [16][17] Reporting and Accountability - Independent directors must submit an annual report detailing their activities, including attendance at meetings and communication with shareholders [28][29] - They are required to maintain confidentiality regarding company secrets even after their term ends [38][39]

烟台正海生物科技股份有限公司 第一章 总则 第一条 为维护烟台正海生物科技股份有限公司（以下简称"公司"）股东及 债权人的合法权益，规范公司股东会的组织和行为，根据《中华人民共和国公司 法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司股东会规则》、《上市公司章程指引》等法律、法规、规范性文件及《烟 台正海生物科技股份有限公司章程》（以下简称《公司章程》），制订本议事规则 （以下简称"本规则"）。 第二章 一般规定 第二条 股东会是公司的权力机构，依法行使下列职权： （六）对公司合并、分立、解散、清算或者变更公司形式作出决议； （十六）对公司因减少公司注册资本、与持有本公司股票的其他公司合并情 形而发生收购本公司股份的事项； （十七）公司年度股东会可以授权董事会决定向特定对象发行融资总额不超 过人民币 3 亿元且不超过最近一年末净资产 20%的股票，该授权在下一年度股东 会召开日失效； （一）单笔担保额超过公司最近一期经审计净资产 10%的担保； （二）公司及其控股子公司的提供担保总额，超过公司最近一期经审计净资 产 50%以后提供的任何担保； （三）为资产负债率超过 7 ...

烟台正海生物科技股份有限公司董事会 薪酬与考核委员会工作细则 第一章 总 则 第二条 薪酬与考核委员会为董事会下设的专门委员会，主要负责制定公司董事及高 级管理人员的考核标准并进行考核；负责制定、审查公司董事及高级管理人员的薪酬政 策与方案，对董事会负责。 第三条 本工作细则所称董事是指在本公司支取薪酬的董事，高级管理人员是指董事 会聘任的总经理、副总经理、董事会秘书、财务负责人以及董事会确定的其他高级管理 人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由 3 名董事组成，其中独立董事 2 名。 第五条 薪酬与考核委员会委员（以下简称"委员"）由董事长、1/2 以上独立董事 或者全体董事的 1/3 以上提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员（召集人）1 名，由独立董事担任，负责主持 委员会工作。委员会主任委员由董事会指定。 当委员会主任委员不能或无法履行职责时，由其指定一名其他委员代行其职权；委 员会主任委员既不履行职责，也不指定其他委员代行其职责时，任何一名委员均可将有 关情况向公司董事会报告，由董事会指定一名委员履行薪酬与考核委员会主任委员职责。 第一条 为进一步建立健全烟 ...

烟台正海生物科技股份有限公司 章程 烟台正海生物科技股份有限公司 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第五章 董事和董事会 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第六章 高级管理人员 第七章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第八章 通知和公告 第一节 通知 第二节 公告 第九章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十章 修改章程 第十一章 附则 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）和其他有关规定，制订本章程。 ...